Janux Therapeutics (JANX) Share-based Compensation (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Share-based Compensation of $28.5 million for Q1 2026, up 166.31% year-over-year from $10.7 million in Q1 2025, and up 199.53% quarter-over-quarter from $9.5 million in Q4 2025.
Janux Therapeutics (JANX) Share-based Compensation (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Share-based Compensation for 7 consecutive years, with $28.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 166.31% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (down 25.19% YoY), while the FY2025 annual figure was $57.6 million, up 74.44% from the prior year.
- Share-based Compensation improved to $28.5 million in Q1 2026 per JANX's latest filing, from $9.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $75.9 million in Q2 2025 and bottomed at $4.0 million in Q1 2022.
- Historically, Share-based Compensation has averaged $15.1 million across 5 years, with a median of $5.6 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 1323.74% — and 2023, when it fell 1.04%.
- Janux Therapeutics' Share-based Compensation stood at $4.2 million in 2022, then rose by 6.61% to $4.5 million in 2023, then jumped by 39.44% to $6.3 million in 2024, then soared by 52.22% to $9.5 million in 2025, then soared by 199.53% to $28.5 million in 2026.
- Business Quant data shows JANX's Share-based Compensation at $28.5 million in Q1 2026, $9.5 million in Q4 2025, and $61.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 52.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.30 Mn |
| Jun 30, 2026 | 52.30 Mn |
| Mar 31, 2026 | 28.50 Mn |
| Mar 31, 2026 | 28.50 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Sep 30, 2025 | 61.20 Mn |
| Sep 30, 2025 | 61.20 Mn |
| Jun 30, 2025 | 75.90 Mn |
| Jun 30, 2025 | 75.90 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 15.39 Mn |
| Sep 30, 2024 | 15.39 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 5.63 Mn |
| Mar 31, 2024 | 5.63 Mn |